Compare Oatly Group AB - ADR (OTLY) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oatly Group AB - ADR vs Viatris Inc — how do they compare? Oatly Group AB - ADR trades at $10.86 (market cap $282.27M), while Viatris Inc trades at $17.02 (market cap $20.50B). The key difference: Viatris Inc is far larger — about 72.6× Oatly Group AB - ADR's market cap, and Viatris Inc pays a 2.73% dividend while Oatly Group AB - ADR pays none. Which is the better fit depends on your goals.
| OTLY | VTRS | |
|---|---|---|
Market Cap | $282.27M | $20.50B |
Sector | Consumer Staples | Health |
52-Week High | $18.54 | $17.59 |
52-Week Low | $8.03 | $8.74 |
Enterprise Value | $779.89M | $32.71B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Oatly (OTLY) trades at $9.05, down 9.86% in the last session, with a neutral technical signal. The company shows modest revenue growth to $862M in 2025 but continues to report significant losses with a -17.06% net margin. Cash flow remains negative at -$35M, though improving from previous years. Recent news highlights new product launches and upcoming Q2 2026 earnings on July 22.
The outlook remains challenging with persistent losses and high debt levels creating financial strain. Analyst sentiment is mixed with 44% buy ratings but 50% hold, reflecting uncertainty about profitability timeline. Key risks include cash burn sustainability and competitive pressure in the plant-based beverage market.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
